Immunotoxin-mediated inhibition of chronic lymphocytic leukemia cell proliferation in humans.

We evaluated the cytotoxicity of the immunotoxin OKT1-SAP on fresh B-chronic lymphocytic leukemia (B-CLL) cells from 31 consecutive patients. OKT1-SAP comprised the OKT1 (CD5) monoclonal antibody disulfide linked to saporin-6 (SAP) ribosome-inactivating protein from the plant Saponaria officinalis. The effect of OKT1-SAP on target CD5-positive B-CLL cells was estimated using an in vitro proliferation inhibition assay in which control or OKT1-SAP-treated B-CLL cells were induced to proliferate by sequential stimulation with insolubilized anti-C3b receptor CB04 (CD35) antibody and low molecular weight B-cell growth factor. In 90% of patients, OKT1-SAP specifically suppressed B-CLL cell proliferation in a dose-related manner (50% inhibitory concentration, 4.0-6.8 nM). Taken together the findings reported in this article provide information relevant to the clinical development of immunotoxins because: (a) the in vitro conditions under which B-CLL cell proliferation is inhibited by OKT1-SAP are achievable in vivo without nonspecific toxicity according to our previous toxicology and pharmacokinetics studies in primates; and (b) the B-CLL cell proliferation inhibition assay described here provides a basis for future comparative studies.

[1]  G. Bonadonna,et al.  Evaluation of antihuman T lymphocyte saporin immunotoxins potentially useful in human transplantation. , 1988, Transplantation.

[2]  D. Johnson,et al.  Inhibition of human T-cell tumor growth by T101-ricin A-chain in an athymic mouse model. , 1988, Cancer research.

[3]  G. Bonadonna,et al.  Synthesis and characterization of an antihuman T-lymphocyte saporin immunotoxin (OKT1-SAP) with in vivo stability into nonhuman primates. , 1988, Blood.

[4]  F. Stirpe,et al.  Modification of ribosomal RNA by ribosome-inactivating proteins from plants. , 1988, Nucleic acids research.

[5]  M. Borowitz,et al.  A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia. , 1988, Journal of biological response modifiers.

[6]  E. Vitetta,et al.  Redesigning nature's poisons to create anti-tumor reagents. , 1987, Science.

[7]  F. Malavasi,et al.  C3b receptors mediate the growth factor-induced proliferation of malignant B-chronic lymphocytic leukemia lymphocytes. , 1987, Leukemia.

[8]  S. Siena,et al.  Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD5) ricin A-chain immunotoxin. , 1987, Blood.

[9]  D. Vallera,et al.  Antigenic modulation by anti-CD5 immunotoxins. , 1986, Journal of immunology.

[10]  P. Casellas,et al.  Study of the plasma clearance of antibody--ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. , 1986, European journal of biochemistry.

[11]  P. Casellas,et al.  Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. , 1986, Blood.

[12]  F. Stirpe,et al.  An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. , 1985, Journal of the National Cancer Institute.

[13]  I. Royston,et al.  Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. , 1980, Journal of immunology.